Search hospitals > New Jersey > Trenton
The Cancer Institute of New Jersey Hamilton
Claim this profileTrenton, New Jersey 08690
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Colorectal Cancer
94 reported clinical trials
10 medical researchers
Summary
The Cancer Institute of New Jersey Hamilton is a medical facility located in Trenton, New Jersey. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer and other specialties. The Cancer Institute of New Jersey Hamilton is involved with conducting 94 clinical trials across 98 conditions. There are 10 research doctors associated with this hospital, such as Howard S. Hochster, Missak Haigentz, MD, Eugenia Girda, MD, and Patrick M. Boland.Area of expertise
1Breast Cancer
Global LeaderER positive
HER2 negative
PR positive
2Cancer
Global LeaderStage III
ER positive
HER2 positive
Top PIs
Howard S. HochsterRutgers Cancer Institute of New Jersey4 years of reported clinical research
Expert in Colorectal Cancer
Studies Colon Cancer
17 reported clinical trials
37 drugs studied
Missak Haigentz, MDRutgers Cancer Institute of New Jersey3 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
14 reported clinical trials
23 drugs studied
Eugenia Girda, MDRutgers Cancer Institute of New Jersey4 years of reported clinical research
Studies Cancer
Studies Ovarian Cancer
14 reported clinical trials
29 drugs studied
Patrick M. BolandRutgers Cancer Institute of New Jersey4 years of reported clinical research
Studies Colon Cancer
Studies Colorectal Cancer
9 reported clinical trials
18 drugs studied
Clinical Trials running at The Cancer Institute of New Jersey Hamilton
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Gallbladder Cancer
Prostate Cancer
Cancer
Small Cell Lung Cancer
Colorectal Cancer
ALK Gene Rearrangement
Recurrence
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Omitting Radiation Therapy
for Breast Cancer
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at The Cancer Institute of New Jersey Hamilton?
The Cancer Institute of New Jersey Hamilton is a medical facility located in Trenton, New Jersey. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer and other specialties. The Cancer Institute of New Jersey Hamilton is involved with conducting 94 clinical trials across 98 conditions. There are 10 research doctors associated with this hospital, such as Howard S. Hochster, Missak Haigentz, MD, Eugenia Girda, MD, and Patrick M. Boland.